Cabotegravir–rilpivirine treatment initiation in a nonvirologically suppressed patient

Early adopters of long-acting injectable cabotegravir/rilpivirine: what lessons can we learn?

“…The potential benefits and risks of LAI CAB/ RPV for individuals with detectable viremia and/or a history of missed doses of oral ART is a topic of ongoing study and debate. Promising data on the potential role for LAI CAB/RPV in the setting of viremia have been published in case reports, case series, and one open-label demonstration study, though national guidelines still advise against prescribing this option in the setting of viremia [2][3][4][5][6]. The findings from SCOLTA indicate that there are clinical instances in which LAI CAB/RPV may be the optimal ART choice in the setting of low-level viremia, and greater detail and understanding of the cases in which this option was selected despite viremia would benefit the field.…”